Novartis to seek full FDA approval for IgAN drug Vanrafia despite missing ph. 3 kidney function goal
It’s déjà vu all over again. Just as the kidney disease space becomes increasingly competitive, Novartis has found itself intending to turn a statistical miss into a regulatory win. | It’s déjà vu all ...
Adults living with idiopathic hypersomnia and narcolepsy type 1 often report cognitive difficulties, including problems with memory, attention, and mental fatigue. However, new research published in ...
Once a top prospect, Zac Veen has opened up about his struggles and why he has done a complete turnaround this offseason.
PROPEL 3 successfully met the primary endpoint of change from baseline in AHV at Week 52 (p<0.0001)- Change from baseline in AHV was ...
Hot nights during pregnancy tied to autism in study tracking 300,000 births. Risk increased during specific developmental ...
Infigratinib is an investigational oral therapy designed to directly inhibit FGFR3 protein phosphorylation, addressing the underlying cause of achondroplasia.
The Fetal Medicine Foundation (FMF) method for early risk assessment and aspirin prophylaxis showed no significant reduction ...
Speed-of-processing training with booster sessions was tied to a lower dementia risk over a 20-year period. Memory and ...
Retrospective analysis compares smooth and perforated polyetheretherketone implants, revealing trends in postoperative ...
An fresh look at trial results that propelled the only FDA approval of a chimeric antigen receptor (CAR) T-cell therapy for mantle cell lymphoma (MCL) shows prior treatment with ibrutinib, a ...
Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease The Phase 2 study ...
For decades, psychologists have argued over a basic question. Can one grand theory explain the human mind, or do attention, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results